Osteoarthritis Management in Canine Health

Osteoarthritis is a progressive, degenerative joint disease characterised by cartilage erosion, subchondral bone remodelling and synovial inflammation that leads to pain, lameness and reduced quality of life in dogs. It affects multiple joints, most commonly the elbow, hip, stifle and tarsus, and carries a substantial welfare and economic burden worldwide. Risk factors include breed predisposition, advanced age, excess body weight and prior joint injury, and early radiographic changes often precede overt clinical signs. Management adopts a multimodal strategy combining weight control, controlled exercise, physiotherapy and pharmacological analgesia, typically non-steroidal anti-inflammatory drugs. Adjunctive approaches encompass nutraceuticals such as omega-3 fatty acids and botanical extracts, alongside regenerative techniques including intra-articular platelet-rich plasma, mesenchymal stem cell therapies and novel biomaterials. Surgical interventions—ranging from joint decompression to total hip replacement—are reserved for advanced cases. A comprehensive, individualised plan aiming to restore joint homeostasis, relieve pain and maintain mobility underpins current best practice.

Research from Nature Portfolio

A large-scale screening of young dogs at routine practice revealed that radiographic signs of osteoarthritis are common even in animals under four years of age, with nearly 40 % demonstrating degenerative changes and 20 % experiencing concurrent pain despite minimal clinical recognition or treatment. This underdiagnosis in early stages underscores the need for proactive screening and owner education. A parallel analysis of primary-care records in the UK identified appendicular osteoarthritis in approximately 2.5 % of the canine population annually, with affected dogs spending over 10 % of their life span under disease-related impairment. Breed, neuter status, insurance and elevated bodyweight emerged as significant predictors, emphasising the importance of targeted prevention and monitoring programmes in at-risk cohorts.

Osteoarthritis Management in Canine Health publication trend

The graph below shows the total number of articles in osteoarthritis management in canine health across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoarthritis: Chronic degenerative joint condition marked by cartilage loss, osteophyte formation and synovial inflammation.

Mesenchymal stem cells (MSCs): Multipotent progenitor cells capable of differentiating into chondrocytes and modulating inflammation.

Platelet-rich plasma (PRP): Concentrated autologous plasma fraction rich in growth factors used to promote tissue repair.

Nutraceuticals: Dietary supplements with therapeutic intent, including omega-3 fatty acids and antioxidants.

Radiographic osteoarthritis (rOA): Imaging-based evidence of joint degeneration, such as joint space narrowing and osteophyte development.

References

1. Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing. Arthritis Research & Therapy (2023).
2. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Scientific Reports (2024).
3. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Scientific Reports (2018).
4. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. International Journal of Molecular Sciences (2022).
5. A placebo-controlled study comparing the efficacy of intra-articular injections of hyaluronic acid and a novel hyaluronic acid-platelet-rich plasma conjugate in a canine model of osteoarthritis. Journal of Orthopaedic Surgery and Research (2019).